Severe Myocarditis after Nivolumab and Ipilimumab in a Patient with Microsatellite Instability-High Gastric Adenocarcinoma: A Case Report

Read full text Summarise with VIRAT
Authors: Sezai Tunç, Oğur Karhan, A Koç
Cited by: 0
References: 10

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Myocarditis attributable to immune checkpoint inhibitors is regarded as among the most serious complications of immunotherapeutic treatment. We report a case of gastric cancer who developed myocarditis, and subsequent late complications following treatment with nivolumab and ipilimumab. The patient was managed with corticosteroids, mycophenolate mofetil (MMF), and intravenous immunoglobulin G (IVIG), but later developed supraventricular tachycardia and deep vein thrombosis. This report emphasizes the need to enhance recognition of immune-related toxicities within non-oncology specialties to support prompt interdisciplinary collaboration and appropriate patient management. Additionally, patients can develop myocarditis-related complications even when clinically stable or near the end of treatment, underscoring the need for close and ongoing monitoring.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Viral Infections and Immunology Research Chemotherapy-induced cardiotoxicity and mitigation

Publication details

Journal / source
Nigerian Journal of Clinical Practice
Volume
29
Issue
3
Pages
356–359
Publication date
1 March 2026
Language
EN